These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 34813613)
21. Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis. Min H; Fan S; Song S; Zhuang Y; Li H; Wu Y; Cai H; Yi L; Dai J; Gao Q Diagn Pathol; 2016 Nov; 11(1):135. PubMed ID: 27881157 [TBL] [Abstract][Full Text] [Related]
22. Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique. Maher TM; Whyte MK; Hoyles RK; Parfrey H; Ochiai Y; Mathieson N; Turnbull A; Williamson N; Bennett BM Adv Ther; 2015 Oct; 32(10):929-43. PubMed ID: 26498943 [TBL] [Abstract][Full Text] [Related]
24. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis. Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N Respirology; 2020 Mar; 25(3):275-280. PubMed ID: 31270920 [TBL] [Abstract][Full Text] [Related]
25. Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments. Luo X; Xiang F J Thorac Dis; 2024 Jul; 16(7):4727-4741. PubMed ID: 39144320 [TBL] [Abstract][Full Text] [Related]
26. Survival from an Acute Exacerbation of Idiopathic Pulmonary Fibrosis with or without Direct Hemoperfusion with a Polymyxin B-immobilized Fiber Column: A Retrospective Analysis. Oishi K; Aoe K; Mimura Y; Murata Y; Sakamoto K; Koutoku W; Matsumoto T; Ueoka H; Yano M Intern Med; 2016; 55(24):3551-3559. PubMed ID: 27980253 [TBL] [Abstract][Full Text] [Related]
27. The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia. Arnold DM; Vrbensky JR; Karim N; Smith JW; Liu Y; Ivetic N; Kelton JG; Nazy I Br J Haematol; 2017 Jul; 178(2):302-307. PubMed ID: 28444742 [TBL] [Abstract][Full Text] [Related]
28. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083 [TBL] [Abstract][Full Text] [Related]
29. The Activities of Daily Living after an Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Koyama K; Sakamoto S; Isshiki T; Shimizu H; Kurosaki A; Homma S Intern Med; 2017 Nov; 56(21):2837-2843. PubMed ID: 28943534 [TBL] [Abstract][Full Text] [Related]
30. Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Cao M; Swigris JJ; Wang X; Cao M; Qiu Y; Huang M; Xiao Y; Cai H Mediators Inflamm; 2016; 2016():6940480. PubMed ID: 27642238 [TBL] [Abstract][Full Text] [Related]
32. Prognostic evaluation by oxygenation with positive end-expiratory pressure in acute exacerbation of idiopathic pulmonary fibrosis: A retrospective cohort study. Suzuki A; Taniguchi H; Ando M; Kondoh Y; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Sakamoto K; Hasegawa Y Clin Respir J; 2018 Mar; 12(3):895-903. PubMed ID: 28026113 [TBL] [Abstract][Full Text] [Related]
33. Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study. Cano-Jiménez E; Romero Ortiz AD; Villar A; Rodríguez-Nieto MJ; Ramon A; Armengol S Respir Res; 2022 Sep; 23(1):235. PubMed ID: 36071483 [TBL] [Abstract][Full Text] [Related]
34. Associations of Serological Biomarkers of sICAM-1, IL-1 Li X; Zhou Y; Zou R; Chen H; Liu X; Qiu X; Xiao Y; Cai H; Dai J Mediators Inflamm; 2020; 2020():4534272. PubMed ID: 32694925 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study. Abe M; Tsushima K; Matsumura T; Ishiwata T; Ichimura Y; Ikari J; Terada J; Tada Y; Sakao S; Tanabe N; Tatsumi K Drug Des Devel Ther; 2015; 9():5755-62. PubMed ID: 26566367 [TBL] [Abstract][Full Text] [Related]
36. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Sakamoto S; Homma S; Miyamoto A; Kurosaki A; Fujii T; Yoshimura K Intern Med; 2010; 49(2):109-15. PubMed ID: 20075573 [TBL] [Abstract][Full Text] [Related]
37. The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial. Kulkarni T; Newton CA; Gupta S; Samara K; Bernstein EJ Pulm Ther; 2024 Sep; 10(3):331-346. PubMed ID: 39073523 [TBL] [Abstract][Full Text] [Related]
38. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235 [TBL] [Abstract][Full Text] [Related]
39. Steroid therapy in acute exacerbation of fibrotic interstitial lung disease. Koshy K; Barnes H; Farrand E; Glaspole I Respirology; 2024 Sep; 29(9):795-802. PubMed ID: 38825348 [TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of Serum Osteopontin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Gui X; Qiu X; Xie M; Tian Y; Min C; Huang M; Hongyan W; Chen T; Zhang X; Chen J; Cao M; Cai H Biomed Res Int; 2020; 2020():3424208. PubMed ID: 32104688 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]